Top Cardiology Trials of 2022

Trials on heart failure, hypertension and lipid-lowering drugs, and the evolution of antithrombin and antiplatelet therapy are discussed in part 2 of cardiologists Bob Harrington and Mike Gibson's annual review.

This podcast is intended for healthcare professionals only.

To read a transcript or to comment, visit

https://www.medscape.com/author/bob-harrington

Lipid Lowering

Safety, Tolerability and Efficacy of Up-Titration of Guideline-Directed Medical Therapies for Acute Heart Failure (STRONG-HF): A Multinational, Open-Label, Randomised, Trial

https://doi.org/10.1016/S0140-6736(22)02076-1

Why Combination Lipid-Lowering Therapy Should Be Considered Early in the Treatment of Elevated LDL-C for CV Risk Reduction

https://www.acc.org/latest-in-cardiology/articles/2022/06/01/12/11/why-combination-lipid-lowering-therapy-should-be-considered

Incidental Coronary Artery Calcium: Opportunistic Screening of Prior Non-gated Chest CTs to Improve Statin Rates (NOTIFY-1 Project)

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.062746

Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease

https://doi.org/10.1016/j.jacc.2022.09.021

Comparative Effects of Low-Dose Rosuvastatin, Placebo and Dietary Supplements on Lipids and Inflammatory Biomarkers

https://doi.org/10.1016/j.jacc.2022.10.013

Antihypertensive Drugs

No Survival Advantage for Either Torsemide or Furosemide in HF: TRANSFORM-HF

https://www.medscape.com/viewarticle/983611

Chlorthalidone vs. Hydrochlorothiazide for Hypertension–Cardiovascular Events

www.nejm.org/doi/full/10.1056/NEJMoa2212270

Antiplatelets

Duration of Antiplatelet Therapy After Complex Percutaneous Coronary Intervention in Patients at High Bleeding Risk: A MASTER DAPT Trial Sub-analysis

https://doi.org/10.1093/eurheartj/ehac284

PANTHER: Should Clopidogrel Become the 'New Aspirin' in CAD?

https://www.medscape.com/viewarticle/980117

P2Y12 Inhibitor Versus Aspirin Monotherapy for Secondary Prevention of Cardiovascular Events: Meta-analysis of Randomized Trials

https://doi.org/10.1093/ehjopen/oeac019

Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes

https://doi.org/10.1056/nejmoa0904327

TCT-320 Pharmacokinetic and Pharmacodynamic Profile of PL-ASA, a Novel Phospholipid-Aspirin Complex Liquid Formulation, Compared to Enteric-Coated Aspirin at an 81-mg Dose – Results From a Prospective, Randomized, Crossover Study

https://www.jacc.org/doi/10.1016/j.jacc.2021.09.1173

Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation

https://europepmc.org/article/pmc/pmc8773391

Antithrombins/Factor XI

Rivaroxaban in Patients With a Recent Acute Coronary Syndrome

https://www.nejm.org/doi/full/10.1056/nejmoa1112277

Genetically Determined FXI (Factor XI) Levels and Risk of Stroke

https://doi.org/10.1161/strokeaha.118.022792

Factor XIa Inhibition With Asundexian After Acute Non-cardioembolic Ischaemic Stroke (PACIFIC-Stroke): an International, Randomised, Double-Blind, Placebo-Controlled, Phase 2b Trial

https://doi.org/10.1016/s0140-6736(22)01588-4

Safety of the Oral Factor Xia Inhibitor Asundexian Compared With Apixaban in Patients With Atrial Fibrillation (PACIFIC-AF): a Multicentre, Randomised, Double-Blind, Double-Dummy, Dose-Finding Phase 2 Study

https://doi.org/10.1016/S0140-6736(22)00456-1

A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction

https://doi.org/10